Suggested remit - To appraise the clinical and cost effectiveness of durvalumab with tremelimumab within its marketing authorisation for untreated metastatic urothelial cancer
Status In progress
Process STA 2018
ID number 1335

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
04 April 2019 Dear Consultees and Commentators As you will be aware the Department for Health and Social Care has asked NICE to conduct an appraisal of durvalumab with tremelimumab for untreated metastatic urothelial cancer. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations. Further information regarding the scheduling of this appraisal will be available in due course.
19 October 2018 - 16 November 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
24 April 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance